Search

Deterministic sensitivity analyses found that the costs of disease management had an impact on results: minimum values generated lower cost savings and a longer break-even point in time (BPT), whereas maximum values of disease management costs generated higher cost savings and a shorter BPT. Anti-HCV therapy worth it in Italy, with initial investment costs recouped after around 4 years An analysis published in I Applied Health Economics and Health Policy i has found that treating newly-diagnosed hepatitis-C virus (HCV) patients would significantly reduce costly disease complications, with initial investment costs recouped within 4.3 years and "in the worst hypothesis, according to the results of the PSA [probabilistic sensitivity analysis], the return of investments is expected 8 years after successful treatment", say the authors. [Extracted from the article]